Maze Therapeutics (NASDAQ:MAZE) Trading 5.5% Higher Following Strong Earnings

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) were up 5.5% during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $33.44 and last traded at $33.4720. Approximately 464,133 shares changed hands during mid-day trading, a decline of 28% from the average daily volume of 640,987 shares. The stock had previously closed at $31.73.

The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised near‑term EPS estimates across 2026–2029 and boosted FY2030 to $1.00 while maintaining a “Buy” rating and a $110 price target — a strong analyst endorsement that supports upside if development and regulatory paths stay on track. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
• Positive Sentiment: BTIG issued a “Buy” rating, adding further sell‑side support that could attract buyers looking for durable conviction from institutional analysts. Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research
• Positive Sentiment: Phase 2 HORIZON data for MZE829 showed a clinically meaningful ~35.6% mean reduction in proteinuria (uACR), exceeding the ≥30% threshold cited for regulatory relevance — the fundamental clinical readout supports a pathway toward a pivotal trial. Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
• Neutral Sentiment: Technical metrics show the stock moved into oversold territory after the selloff, and some analysts/technicals argue the decline may have exhausted short‑term sellers — this could set up a technical bounce independent of fundamentals. After Plunging 30.8% in 4 Weeks, Here’s Why the Trend Might Reverse for Maze Therapeutics
• Negative Sentiment: Despite positive efficacy, the market treated the Phase 2 results as “mixed” on endpoints/subgroup/readout detail, triggering a steep selloff that wiped nearly a third of market value — heightened volatility and investor uncertainty remain key near‑term risks. Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
• Negative Sentiment: A shareholder law firm (Johnson Fistel) has opened an investigation into potential claims related to MAZE disclosures — this introduces legal/PR risk and could prolong downward pressure if it results in litigation or heightened scrutiny. MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel
• Negative Sentiment: Media coverage captured the paradox of “best‑in‑class potential” commentary alongside a sharp post‑readout plunge, amplifying sentiment swings and increasing short‑term trading risk. After ph. 2 readout, analysts herald best‑in‑class potential as stock plummets

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MAZE. Wedbush lifted their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Guggenheim increased their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Finally, Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $64.11.

Insider Transactions at Maze Therapeutics

In related news, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the transaction, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Amy Bachrodt sold 10,000 shares of the business’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at $526,119.70. This trade represents a 43.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 245,000 shares of company stock worth $10,504,792 in the last ninety days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Royal Bank of Canada grew its holdings in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the period. Ameritas Investment Partners Inc. increased its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. California State Teachers Retirement System raised its stake in Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares during the period. Police & Firemen s Retirement System of New Jersey raised its stake in Maze Therapeutics by 18.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after purchasing an additional 931 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics in the 4th quarter valued at about $39,000.

Maze Therapeutics Trading Down 4.2%

The firm’s fifty day simple moving average is $45.61 and its two-hundred day simple moving average is $37.62. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -9.41 and a beta of 4.47.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.